Clinical Safety Profile

To date, within IRB- (or other comparable ethical review committee) approved international trials and studies and FDA-authorized eINDS, approximately 300 subjects have received treatment with AlloRx Stem Cells via peripheral intravenous infusion or direct injection for potential treatment of a wide variety of indications, including Acute Respiratory Distress Syndrome (“ARDS”) due to COVID-19, Long COVID, MS, ALS, Lupus, MSA, Alzheimer’s disease, CKD, COPD, diabetes and age-related conditions, and there have been no serious adverse events reported that were considered related to AlloRx Stem Cells.